Lung Cancer | Specialty

The Role for Liquid Biopsy in NSCLC

August 29th 2017

Widespread Mutation Testing for NSCLC

August 29th 2017

Genetic Testing for NSCLC

August 29th 2017

Optimizing Immunotherapy Remains a Challenge in NSCLC

August 29th 2017

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Dr. Vokes on PARP Inhibitors for NSCLC

August 29th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses PARP inhibitors for patients with non-small cell lung cancer (NSCLC).

Dr. Diehn on Next Steps With Liquid Biopsies in Lung Cancer

August 25th 2017

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

Dr. Gandara on the MYSTIC Trial for Lung Cancer

August 25th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the MYSTIC trial for patients with non-small cell lung cancer (NSCLC)

Angiogenesis Inhibitor Tested in Mesothelioma Trial

August 21st 2017

Nintedanib, an angiogenesis inhibitor, is being investigated as a first-line treatment for patients with unresectable malignant pleural mesothelioma (MPM).

EGFR-Mutant NSCLC Treatment Paradigm on Verge of Disruption

August 18th 2017

Monotherapy with a tyrosine kinase inhibitor is the frontline standard of care for patients with advanced EGFR-mutant non–small cell lung cancer, with 3 currently approved agents: erlotinib, gefitinib, and afatinib.

Expert Explains Approaches in Non-Driver NSCLC

August 18th 2017

Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.

ASCO Updates Treatment Guidelines for Advanced NSCLC

August 16th 2017

ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.

CRISPR Technology Seeking to Inactivate Mutated Genes in Lung Cancer

August 15th 2017

Monte Winslow, PhD, shares the work on CRISPR being developed in his lab, and how this technology might help advance treatment for the non-driver NSCLC population.

Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

August 15th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond

August 14th 2017

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Liquid Biopsies, NGS Expected to Become Standard in Lung Cancer

August 11th 2017

Maximilian Diehn, MD, PhD, discussed the future of NGS platforms and liquid biopsies and his vision for them eventually becoming standard practice for patients with lung cancer.

Molecular Targets Could Be Unraveled for Patients With Non-Driver NSCLC

August 10th 2017

Millie Das, MD, discusses the difficulties of the non-driver non-small cell lung cancer patient population, interesting clinical trials that could reshape therapeutic options, and her belief that these patients do have molecular targets that have yet to be identified.

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

August 10th 2017

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.

Dr. Neal Debates Whether Alectinib Will Become the Standard Frontline Therapy for ALK+ NSCLC

August 9th 2017

Joel Neal, MD, an assistant professor of medicine and oncology at Stanford Medicine, discusses whether, if approved by the FDA, alectinib (Alecensa) will become the frontline standard of care for patients with ALK-positive non–small cell lung cancer (NSCLC).

Stem Cell Research Aims to Further Personalize Lung Cancer Care

August 9th 2017

Tushar Desai, MD, discusses his research in stem cells and why discovering which cells have the potential to form lung cancer is significant to the treatment paradigm.

Sequencing Switches, Intriguing Combos Being Debated in ALK+ NSCLC

August 8th 2017

Joel Neal, MD, discusses the latest therapeutic changes to the ALK-positive NSCLC armamentarium.